课题基金 / 基金详情

An experimental study on antitumor immuno-gene therapy using dendritic cells genetically modified to express the tumor antigen gene and cytokine gene

An experimental study on antitumor immuno-gene therapy using dendritic cells genetically modified to express the tumor antigen gene and cytokine gene
利用基因修饰表达肿瘤抗原基因和细胞因子基因的树突状细胞进行抗肿瘤免疫基因治疗的实验研究
批准号:
12671170
负责人:
IWAHASHI Makoto
金额:
$2.18万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2000
资助国家:
日本
项目状态:
已结题
起止时间:
2000 至 2002

项目摘要

项目成果

IWAHASHI Makoto的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
In present study, we examined therapeutic efficacy of the immunotherapy using dendritic cells (DCs) genetically engineered to express the tumor antigen, comparing to the immunotherapy using DCs pulsed with the tumor antigen peptide in CT26 tumor models. Moreover, DCs were transduced simultaneously with tumor antigen gene and GM-CSF gene, and we assessed the augmenting effect of cotransduction with GM-CSF gene on therapeutic vaccine therapy. Bone marrow-derived murine DCs were adenovirally transduced with natural tumor antigen gp70 gene of BALB/c-derived CT26 (DC-AxCAgp70), and cotransduced with murine GM-CSF (DC-AxCAgp70/mGM-CSF). On the other hand, DCs were pulsed with AH-1 which is immunodominant peptide of the gp70 (DC/AH-1). The cytotoxic T lymphocyte (CTL) activities induced in the mice immunized with DCs-AxCAgp70 showed significantly higher (40%) than that in the mice immunized with DC/AH-1 (24%)(E/T : 50). Furthermore, CTL activities were enhanced in the mice immunized with DC-AxCAgp70/mGM-CSF (86%). In the subcutaneous tumor model and the orthotopic colon cancer model of CT26, the vaccine therapy using DC-AxCAgp70 showed much more remarkable inhibition of tumor growth than the vaccination using DC/AH-1 (p<0.0001), which was reflected in resulting in the prolongation of the survival periods. Antitumor responses were augmented by cotransduction with mGM-CSF gene to DC-AxCAgp70. CC chemokine receptor 7 mRNA expression on DCs, which would play an important role in the migration of DCs to regional lymph nodes was induced by adenoviral transduction with gp70 gene, and more enhanced by cotransduction with mGM-CSF gene. In contrast, it was not detected in AH-1-pulsed DCs. These results suggested that the vaccination using DCs transduced with both the tumor antigen gene and cytokine gene could be a more potent strategy for therapeutic antitumor immunotherapy.
期刊论文(24)
专著(0)
科研奖励(0)
会议论文
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Ueda K et al.: "Carcinoembryonic antigen (CEA)-specific suicide gene therapy of cytosine deaminase (CD)/5-FC enhanced by Cre/loxP system in the orthotopic gastric carcinoma model"Cancer Res. 61. 6158-6162 (2001)
Ueda K等人:“在原位胃癌模型中Cre/loxP系统增强了胞嘧啶脱氨酶(CD)/5-FC的癌胚抗原(CEA)特异性自杀基因治疗”Cancer Res。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Nagata T et al.: "Overexpression of pyrimidine nucleoside phosphorylase enhances the sensitivity to 5'-deoxy-5-fluorouridine in tumour cells in vitro and in vivo"Eur J Cancer. 38. 712-717 (2002)
Nagata T 等人:“嘧啶核苷磷酸化酶的过度表达增强了体外和体内肿瘤细胞对 5-脱氧-5-氟尿苷的敏感性”Eur J Cancer。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Ueda K et al.: "Improvement of carcinoembryonic antigen-specific prodrug gene therapy for experimental colon cancer"Surgery. (in press).
Ueda K等人:“实验性结肠癌癌胚抗原特异性前药基因治疗的改进”手术。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
20
    Development of novel therapy targeting IL-17 in tumor microenvironment
    • 批准号:
      22591415
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.75万
    • 财政年份:
      2010
    • 负责人:
      IWAHASHI Makoto
    • 依托单位:
    Novel therapeutic target for regulation of inflammation in tumor microenvironment
    • 批准号:
      19591493
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.41万
    • 财政年份:
      2007
    • 负责人:
      IWAHASHI Makoto
    • 依托单位:
    Cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen and cytokines
    Development of new tumor specific gene therapy in gastrointestinal carcinoma
    海外基金